Trial Profile
Pharmacodynamic comparison of different oral P2Y12-receptor inhibitor loading strategies for transitioning from cangrelor in patients undergoing coronary stenting
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jun 2020
Price :
$35
*
At a glance
- Drugs Cangrelor (Primary) ; Clopidogrel; Prasugrel; Ticagrelor
- Indications Coronary disorders
- Focus Therapeutic Use
- Acronyms ExcelsiorLOAD2
- 01 Feb 2018 Results assessing the impact of Reticulated Platelets on the Antiplatelet Effect of Cangrelor, published in the Thrombosis and Haemostasis
- 01 Sep 2017 Results published in the ESC Congress 2017: Annual Congress of the European Society of Cardiology
- 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology